Free Newsletter

  Email address:
   

Site Search

Agenix Announces Initial China Sales of Hep B Drug YouHeDing

publication date: Jan 4, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Australian biotech Agenix reported that its new treatment for hepatitis B notched sales of 10 million RMB ($1.4 million) in December, its first month on the market. YouHeDing, as the treatment is known, was approved by the SFDA in October 2007. According to Agenix, YouHeDing (adefovir dipivoxil tablets) has a novel crystalline structure when compared to other approved versions of adefovir dipivoxil. It is the first triclinic structured form of the drug developed and patented in China. More details...

Stock Symbol: (ASX: AGX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio Events

September 19, 2008
San Francisco, CA 

 

October 24, 2008
Beijing, China

>> More details...

Partner Events
 
September 16-18, 2008
  San Francisco, CA
 
October 11-13, 2008
Dalian, China
 
November 9-11, 2008
Shanghai, China

>> More details...

Partners